This is a Spanish-language edition of our flagship India market-entry webinar, designed specifically for LATAM exporters. The full slide deck is bilingual; the session is conducted in Spanish with English Q&A optional.
Taevas
On-demandMedical DevicesPharmaceuticalsPersonal Care & BeautyFood & Dietary Supplements
India Market Entry Simplified: Authorized Agent Services for Global Brands (Spanish)
Conducted in Spanish. Unlock key insights for entering India's market via the Authorized Agent / IAR pathway — regulations, licensing, consumer trends, and the role of an IAR in ensuring compliance. Spanish-language session by special request from the LATAM cohort.
10 April 20251h2 time zones
Recording
Watch the full session
Free to watch in full · slides linked below
What you'll learn
Four big things you walk away with
Practical, no-fluff takeaways you can act on the same week.
How CDSCO's evolving Risk-Based Classification reshapes import-licence pathways
When you need an Indian Authorized Representative (IAR) and what the IAR is legally responsible for
Pricing, branding and channel strategies that work for the Indian middle market
Operational realities — bonded warehousing, port clearance, post-market surveillance
Agenda
How the 60-minute session runs
Tight, well-rehearsed, and always ends on time.
- 00:00 – 03:00
Welcome and housekeeping
Introductions, attendee map, audio check.
- 03:00 – 12:00
Market context and the regulator lens
Snapshot of growth drivers, recent regulatory shifts, and what changed in the past 12 months.
- 12:00 – 30:00
Step-by-step: licence pathway walk-through
Live walk-through of the documents, dossiers, and decision points an entering brand will face.
- 30:00 – 42:00
Operational realities post-approval
Vigilance, renewals, port clearance, recall procedures, change-control.
- 42:00 – 55:00
Live Q&A
Open-floor questions answered by the speaker.
- 55:00 – 60:00
Closing and next steps
How to book a 1:1 follow-up consultation and access the slide deck.
Hosted by
Meet the speaker
Ishita Singh
Director · Global Market EntryIndia HQ
Ishita leads Taevas' Global Market Entry practice from Bangalore. She has helped 200+ international medical-device, pharma and consumer-health brands navigate Indian Authorized Representative (IAR) workflows, CDSCO licensing and post-market surveillance — and routinely speaks on the same topics for ECRM, ChemLinked, and the Indian Medical Devices Forum.
Connect on LinkedInRelated sessions
More from the same series
Upcoming
1h
Aug
13
2026
Brazil Pharma Annual Update — RDC 751/2022 in Practice and 2026 Pricing Realities
A São Paulo-led briefing on what it actually takes to launch and price a pharmaceutical product in Brazil today — ANVISA dossier expectations, CMED pricing pathways, post-launch SUS dynamics, and the most common rejection reasons in 2026.
4 takeaways6-step agenda2 zones
Roberta Maria Rodrigues
Head of Brazil Operations · Brazil
Pharmaceuticals
RegisterUpcoming
1h
Jul
09
2026
India's Personal Care Boom — IAR-Led Market Entry for D2C and Modern-Trade Brands
How a competent Indian Authorized Representative shortens a 14-month entry into 4–5. Channel strategy, Nykaa/Amazon onboarding, BIS compliance, ladder pricing, and Instagram-led D2C builds — all condensed into one hour.
4 takeaways6-step agenda2 zones
Ishita Singh
Director · Global Market Entry · India HQ
Personal Care & Beauty
RegisterUpcoming
45 min
Jun
11
2026
EU MDR — What's Changed in 2026 and Why It Matters for Non-EU Brands
A focused 45-minute briefing on the 2026 EU MDR amendments — extended Article 120 transitional periods, the digital UDI pilot, and how Authorised Representative obligations have shifted. Aimed at non-EU brands holding (or seeking) CE marking.
4 takeaways6-step agenda2 zones
Michael Lambell
EU Pharma Lead · United Kingdom
Medical DevicesPharmaceuticals
Register